Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15232


Purpose:

RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well arsenic trioxide works in treating patients with metastatic liver cancer that cannot be removed by surgery.


Study summary:

OBJECTIVES: - Determine the efficacy of arsenic trioxide in patients with unresectable metastatic hepatocellular carcinoma. - Determine the safety and tolerability of this drug in these patients. OUTLINE: Patients receive a loading dose of arsenic trioxide IV over 1-2 hours once daily on days 1-5* in week 1 and then twice weekly in weeks 2-8. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *The 5-day loading dose is only administered during course 1. After completion of study treatment, patients are followed at 30 days and then periodically for up to 2 years. PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed hepatocellular carcinoma - Unresectable metastatic disease - Ascites allowed provided it is minimal PATIENT CHARACTERISTICS: Age - Over 18 Performance status - 0-2 Life expectancy - Not specified Hematopoietic - WBC > 2,500/mm^3 - Absolute neutrophil count > 1,500/mm^3 - Platelet count > 75,000/mm^3 Hepatic - Bilirubin < 2.5 mg/dL - AST < 2.5 times upper limit of normal Renal - Not specified Cardiovascular - QTc interval ≤ 460 msec AND potassium and magnesium normal Other - Not pregnant or nursing - Negative pregnancy test - Fertile female patients must use effective double-method contraception for ≥ 4 weeks before, during, and for ≥ 4 weeks after completion of study treatment (during and for ≥ 4 weeks after completion of study treatment for male patients) - No blood, ova, or sperm donation during study treatment - Potassium > 4.0 mEq/dL - Magnesium > 1.8 mg/dL PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent biologic therapy Chemotherapy - More than 4 weeks since prior and no other concurrent chemotherapy Endocrine therapy - Not specified Radiotherapy - More than 4 weeks since prior and no concurrent radiotherapy Surgery - Not specified Other - No other concurrent investigational agents


NCT ID:

NCT00128596


Primary Contact:

Study Chair
T. Clark Gamblin, MD
UPMC Cancer Center at UPMC Presbyterian


Backup Contact:

N/A


Location Contact:

Pittsburgh, Pennsylvania 15232
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.